Latham Advises on Beta Bionics’ US$150 Million Public Offering of Common Stock and Pre-Funded Warrants

Beta Bionics, Inc. (Nasdaq: BBNX) has announced the pricing of an underwritten public offering of 7,652,175 shares of its common stock at a price to the public of US$17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a purchase price of US$17.2499 per share, which equals the public offering price per share of the common stock less the US$0.0001 exercise price per share of each pre-funded warrant. The gross proceeds from this offering are expected to be US$150 million, before deducting underwriting discounts and commissions and offering expenses payable by Beta Bionics. The offering is expected to close on or about September 17, 2026, subject to customary closing conditions. In addition, Beta Bionics has granted the underwriters for the offering a 30-day option to purchase up to 1,304,348 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Latham & Watkins LLP represents the underwriters in the offering with a Capital Markets team led by New York partner Nathan Ajiashvili and Orange County partner Ross McAloon, with associates Caitlin Nguyen, Abdullah Khan, and Adithi Iyer.